Funding for this research was provided by:
Centers for Disease Control and Prevention (S1734, S043, 1U01DP006266, S3486)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (5-P60 AR49465-03, 5-P60-AR30701, N01-AR-2-2262, N01-AR-2-2258, RC2 AR058950, N01-AR-2-2261, 5-P60 AR062760, N01-AR-2-2260, N01-AR-2-2259)
National Institutes of Health (T32-AG-00262, R01-AR060492, T32-AG-023480, P30-DK-072488)
Received: 8 November 2019
Accepted: 20 February 2020
First Online: 4 March 2020
: The study was approved by the IRB at each clinical center. All participants provided informed consent. The OAI study and public use of clinical and imaging data used in this study were approved by the committee on Human Research at the University of California, San Francisco (IRB# 10–00532). JoCo study was approved by the UNC Office of Human Research Ethics (IRB# 18–0438). GoGo study was approved by the UNC Office of Human Research Ethics (IRB# 99–0807). The Framingham Genetics of Foot Disorders Study was approved by the Institutional Review Board of Hebrew SeniorLife, Protocol #10–009.
: Not applicable.
: None declared.